Background. We address the key emerging question of whether Lin − /CD34
+ hematopoietic precursor cells (HPCs) represent an important latent reservoir of human immunodeficiency virus type 1 (HIV-1) during longterm suppressive therapy.
Methods. To estimate the frequency of HIV-1 infection in bone marrow, we sorted Lin + , and Lin + /CD4 + ) from 8 patients who had undetectable viral loads for 3-12 years. Using a single-proviral sequencing method, we extracted, amplified, and sequenced multiple single HIV-1 DNA molecules from these cells and memory CD4 + T cells from contemporaneous peripheral blood samples.
Results. We analyzed 100 000-870 000 bone marrow Lin − /CD34 + HPCs from the 8 patients and found no HIV-1 DNA. We did isolate HIV-1 DNA from their bone marrow Lin + /CD4 + cells that was genetically similar to HIV-1 DNA from lymphoid cells located in the peripheral blood, indicating an exchange of infected cells between these compartments.
Conclusions. The absence of infected HPCs provides strong evidence that the HIV-1 infection frequency of Lin − /CD34 + HPCs from bone marrow, if it occurred, was <.003% (highest upper 95% confidence interval) in all 8 patients. These results strongly suggest that Lin − /CD34 + HPCs in bone marrow are not a source of persistent HIV-1 in patients on long-term suppressive therapy.
Current antiretroviral therapy (ART) effectively suppresses but does not eradicate HIV-1 infection. During suppressive ART, persistent low-level viremia has been detected in plasma using ultrasensitive assays [1] [2] [3] [4] [5] . The source of this persistent viremia is currently under investigation.
A well-defined latent reservoir of HIV-1 in patients on antiretroviral therapy is memory CD4 + T cells, in which HIV-1 latency is established when an activated CD4 + T cell becomes infected by HIV-1 but transitions to a terminally differentiated memory T cell before HIV-1 infection eliminates the cell [6, 7] . However, there is evidence that other cell types remain infected during effective highly active antiretroviral therapy (HAART) and may contribute to persistent viremia. In 2009, Brennan et al showed that persistent viremia in patients on long-term suppressive therapy was genetically distinct from proviruses in activated CD4 + T cells [8] . In addition, Bailey et al showed that the viral variants found in plasma in 5 of 9 patients on longterm effective HAART were comprised of genetically indistinguishable viral clones that were rarely found in resting CD4 + T cells in the peripheral blood [9] . These findings suggest that cells other than memory CD4 + T cells with proliferative capacity, such as stem cells, could contribute to persistent HIV-1 viremia [8, 9] . 
METHODS

Clinical Specimens
Paired bone marrow and peripheral blood samples from 8 HIV-1 subtype B individuals were analyzed. The samples were obtained from individuals in the Options Cohort at University of California, San Francisco. The Options Cohort is an ongoing longitudinal observational cohort study of adults enrolled within 6 months of HIV-1 antibody seroconversion and followed throughout the course of HIV disease. In this study, we included 5 patients who had elected to begin therapy within 30 days of entering the cohort (acute/early infection, patients 1-5) and 3 who had chosen to begin therapy >1 year after infection (chronic infection, patients 6-8) (Supplementary Table 1 ). The criterion we used for selection of these patients was undetectable HIV-1 viremia (<40-75 copies/mL) for at least 3 years after the initiation of therapy. Informed consent was obtained from all eight patients. The study was approved by the institutional review boards at University of California, San Francisco and the Karolinska Institutet.
Single-Proviral Sequencing
To quantify and genetically characterize HIV-1 viral populations in the cells isolated from bone marrow and peripheral blood we used a modification of the newly developed singlecell sequencing assay [11] called single-proviral sequencing. The details for this assay are reported here.
Isolation of Single Cells from Bone Marrow and Peripheral Blood
Paired bone marrow and blood samples from the 8 patients were collected. The blood specimens were collected using tubes containing acid citrate dextrose as an anticoagulant, and the bone marrow aspirate was collected, following local administration of lidocaine, using 30-mL syringes containing 1 cc of heparin to collect up to 60 mL of bone marrow aspirate. Bone marrow cells and peripheral blood mononuclear cells were separated from plasma using Ficoll.
Fluorescence-Activated Cell Sorting
Fluorescence-activated cell sorting was carried out on a FACSAria (BD Figure 1 . For each cell type, 10
5
-11 × 10 6 cells were sorted into facs tubes.
The cells were then divided into 1.5-mL Eppendorf tubes and spun down. The supernatant was removed, and the pellet was stored at−70°C before being sent on dry ice to Sweden for further analysis.
DNA Amplification and Detection
Cells were lysed by adding 100 µL of lysis buffer, and DNA was released by incubating the samples at 55°C for 1 hour and subsequently at 85°C for 15 minutes [11, 12] . After cell lysis, all samples were stored at −20°C. To obtain polymerase chain reaction (PCR) products derived from single HIV-1 DNA molecules, the cellular lysate with HIV-1 DNA was serially diluted 1:3 in 5-mM Tris-HCl ( pH 8.0) to a maximum dilution of 1:243. According to Poisson's distribution, the cellular dilution yielding PCR product in 3 of 10 PCR reactions contains 1 copy of HIV-1 DNA per positive PCR about 80% of the time. Thus, PCR plates were set up to identify the optimal cellular lysate dilution yielding <30% positive PCR reactions for each cell type and patient by the following procedure. The PCR plates were set up with 8 μL in each of 86 wells containing the following components at the indicated final amounts or concentrations in sterile molecular grade water: 2 × PCR Buffer (Invitrogen), 4 mM MgSO 4 , 400 nM of specific outer primers, 0.08 U/μL Taq platinum polymerase (Invitrogen), and 400 μM nucleotide mix (Promega). Next, 2 µL from each of the different cellular dilutions was added to each well of a PCR row for a total of 10 wells per cellular dilution and a total of 5 rows with cellular dilutions spanning from undiluted to 1:243. Six control wells were included on each PCR plate. A plasmid containing DNA from a laboratory strain ( pNL4-3) of HIV-1 was added to 2 wells as a positive control (1 μL of 10 copies/μL), and molecular-grade water was added to 4 wells as negative controls. The p6-RT region of the HIV-1 DNA in the wells from the plate was then amplified using a nested PCR protocol (outer primers 1894 + and 3500 − ; inner primers 1870 + and 3410 − ) as previously described [11, 13] . Positive HIV-1 DNA amplicons were identified on a 96-well 1% agarose gel with ethidium bromide (Invitrogen). None of the negative control wells were positive. From the number of HIV-1 DNA molecules amplified by PCR, we then determined the cellular dilution yielding <3 HIV-1 amplicons per 10 wells. Using this cellular dilution, up to 8 additional HIV-1 DNA amplification PCR plates were set up for each cell type from each of the 8 patients. The amplified HIV-1 products were sequenced by direct dideoxyterminator sequencing (Applied Biosystems) in both directions using overlapping internal primers [13] .
Our ability to detect single HIV-1 DNA molecules has been shown in an earlier study using 293T cells infected with defined numbers of HIV-based vectors [11] . To further validate the ability of the single-proviral sequencing assay to detect all the HIV-1 DNA molecules in the sorted cell samples, we sorted and analyzed patient samples with known HIV-1 infection frequencies. The frequency of infection of these patient samples was determined previously by single-cell sequencing [11] . The single-proviral sequencing analysis resulted in the amplification of the expected number of HIV-1 DNA molecules for the infection frequencies of these patient samples.
Statistical Methods
Conducting single-proviral sequencing on specific numbers of patient cells, we determined the HIV-1 infection frequency in each cell type using a maximum likelihood statistical analysis. For detailed statistical methods and calculations, please see the Supplementary Material.
Phylogenetic Analyses
Analyses of the intracellular HIV-1 populations were performed using an in-house computer program written in Perl . Using singleproviral sequencing, the amount of HIV-1 DNA was assessed in these HPCs for each patient.
None of the HPCs sorted from the 8 patients were found to contain HIV-1 proviral DNA. The lack of any infected Lin − / CD34 + HPCs in the 8 patients that we studied provides strong evidence that the true infection frequency of these cells in any individual, if it was present, was .0003%-.003% (upper 95% confidence bounds) ( Table 1) . (Figure 1 ). We found a 0.0006%-0.2% infection frequency in the memory T cells isolated from patients who initiated therapy during acute/early infection and a 0.02%-0.4% infection frequency in memory T cells from patients who initiated therapy during chronic infection (for individual values and 95% CI, see Table 1 ). The geometric mean infection frequency of these cells was 13-fold higher in patients who initiated therapy during chronic infection (95% CI, .5-fold-363-fold; P = .08). Using single-proviral sequencing, we sequenced approximately 20 single-proviral HIV-1 genomes from the cells sorted from bone marrow and memory CD4 + T cells sorted from peripheral blood from each of the 8 patients. To evaluate the genetic relationship between the HIV-1 populations in the cells from these 2 different compartments, we conducted phylogenetic analyses (Figure 2) . Sequences from all 8 patient cell samples as well as standard laboratory viruses formed independent populations that were at least 5% different from one another on a phylogenetic tree with no intermingling (data not shown), demonstrating that the viruses found in these patients were genetically distinct. The intrapatient comparisons showed that all 5 patients who initiated therapy during acute/ early infection had nearly monomorphic viral populations derived from the cells located in both compartments (an example is shown in Figure 2A ). The homogeneity of viral sequences in patients with early infection contrasted with the heterogeneity of sequences found in patients with chronic infection (examples shown in Figure 2B ). For all patients analyzed, the phylogenetic distribution of DNA sequences of cells from bone marrow was similar to memory CD4 + T cells derived from peripheral blood taken at the same time (Figure 2A-C) . The genetic similarity between HIV-1 populations in cells from bone marrow and peripheral blood implies that cells from peripheral blood were present in bone marrow specimens or that there is ongoing cellular exchange between these 2 compartments. In samples from patient 7, who initiated therapy in chronic infection, we found identical clonal HIV-1 sequences in cells from both the bone marrow and peripheral blood compartments, which supports this hypothesis. This clonal sequence contains a large 380-base pair deletion, essentially eliminating the protease from this HIV-1 population, indicating this viral population is not replication competent and must result from the expansion cells containing this replication-incompetent HIV-1 population ( Figure 2C ).
HIV-1 Genetic Diversity Is Similar in Cells From Bone Marrow and Peripheral Blood Compartments
To further assess the genetic relationship between HIV-1 populations found in cells from bone marrow and memory CD4 + T cells from peripheral blood, the diversity of sequences from the cells located in these compartments for each patient was calculated using average pairwise distance. In patients who initiated therapy during acute/early infection (1-5), the average pairwise distance of the HIV populations from Lin + /CD4 + cells located in the bone marrow ranged 0.06%-0.17%, and in memory CD4 + T cells from peripheral blood the average pairwise distance ranged 0.08%-0.14%; the corresponding ranges were 0.69%-1.44% and 0.60%-1.37% in patients who initiated therapy in chronic infection ( patients 6-8). The average pairwise distance of the HIV-1 populations located in cells from bone marrow versus peripheral blood were similar, with the within-patient ratios ranging 0.65-1.44 (geometric mean, 1.05; 95% CI, .85-1.31; P = .58), which is consistent with the tree analysis ( Figure 2 ). bone marrow were phylogenetically similar to sequences derived from contemporaneous memory CD4 + T cells from peripheral blood. We also found that the genetic diversity of the HIV-1 populations in these 2 compartments was similar. Interestingly, in patient 7 we found a distinctive viral sequence in both cells isolated from bone marrow and peripheral blood that appears to be replication incompetent. These findings suggest that there is active cellular exchange between the bone marrow and peripheral blood compartments. However, it is also possible that the HIV-1-infected Lin + /CD4 + cells were derived from peripheral blood within the bone marrow. Determining the HIV-1 cellular reservoir during long-term suppressive therapy is crucial so that these cells can be targeted for HIV-1 eradication. Our results provide evidence that Lin − /CD34 + HPCs are not HIV-1 infected. These findings strongly suggest that HPCs are not a major viral reservoir in patients on long-term suppressive therapy. The HIV-1-infected Lin + /CD4 + cells can be isolated from bone marrow.
However, the genetic similarity of the virus in these cells to virus isolated from memory CD4 + T-cells in peripheral blood
indicates an exchange of infected cells between bone marrow and peripheral blood.
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